The Rosen Law Firm Announces Investigation Of Securities Claims Against Catalyst Pharmaceutical Partners, Inc.– CPRX

The Rosen Law Firm announces that it is investigating potential securities fraud claims against Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) resulting from allegations that the Company may have concealed that a competitor has been providing patients for free with a drug that is nearly biologically equivalent to the drug for which Catalyst seeks FDA approval

Catalyst is a development-stage company whose major product is Firdapse. Catalyst seeks FDA approval to sell Firdapse to treat Lambert-Eaton Myasthenic Syndrome ("LEMS"), a serious condition which only affects a few thousand people in the U.S.

But a competitor, Jacobus Pharmaceuticals, makes 3,4-DAP, a drug substantially equivalent to Firdapse. And on October 18, 2013, Adam Feuerstein (a journalist) revealed that Jacobus has been providing 3,4-DAP to patients, for free, pursuant to a number of compassionate use programs, for twenty years. That day, Catalyst's stock price fell from $2.61 to $1.90 on heavy volume, damaging investors.

The Rosen Law Firm is preparing a securities class action lawsuit on behalf of CPRX investors. If you purchased STSI stock before October 18, 2013, please visit the website at for more information. You may also contact Jonathan Horne, Esq., or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at or

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010